Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: John R Resseger who wrote (1144)	1/28/1999 8:26:00 PM
From: Amigo Mike	Read Replies (2) \| Respond to of 1476

Hi John, With regard to Antex's agreement with SmithKline ...... I have access to the agreement. HOWEVER, there are certain parts labeled confidential. I can determine most everything else in the agreement accept milestone money. I do know that SmithKline has the right to continue funding through Sept 2003 and the total payments vary to upwards of $30 million. Antex has already received in the neighborhood of $10.5 million ..... so it is easy to figure that a little less than 2/3rds of the money is still coming down the pike .... Was the banking model what you were looking for ???? Also, there was a rather unique line in the press release that Antex put out yesterday. Apparently no one picked up on it ...... but it states Antex has FOUR candidates in clinical development. It appears that news is forthcoming in the near future regarding the start of trials on another vaccine candidate .............. Moraxella. Antex has already prepared a lot for use in humans. =) Amigo Mike